Zevra Therapeutics (ZVRA) EBIT (2014 - 2026)

Zevra Therapeutics (ZVRA) has 13 years of EBIT data on file, last reported at $52.1 million in Q1 2026.

• Quarterly EBIT rose 1072.51% year-over-year to $52.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$5.4 million (up 92.44% YoY) and the FY2025 annual result came in at -$62.9 million, up 27.65% from the prior year.
• EBIT advanced to $52.1 million in Q1 2026, from $9.3 million in the prior quarter.
• In the past five years, EBIT ranged from a high of $52.1 million in Q1 2026 to a low of -$71.0 million in Q2 2025.
• A 5-year average of -$11.8 million and a median of -$14.0 million in 2023 frame the typical range for EBIT.
• Annual changes were most pronounced in 2022 — EBIT sank 524.6% — and 2026, when it jumped 1072.51%.
• Tracing ZVRA's EBIT over 5 years: stood at -$9.3 million in 2022, then tumbled by 62.75% to -$15.2 million in 2023, then slipped by 1.71% to -$15.4 million in 2024, then soared by 160.42% to $9.3 million in 2025, then soared by 459.81% to $52.1 million in 2026.
• The last three EBIT figures came in at $52.1 million (Q1 2026), $9.3 million (Q4 2025), and $4.1 million (Q3 2025), per Business Quant data.